NIH to invest $70M to increase access to over-the-counter COVID tests

The National Institutes of Health said Oct. 25 it is investing $70 million to bring more at-home COVID-19 tests to market. 

Advertisement

The NIH’s Independent Test Assessment Program plans to establish an accelerated pathway to help the FDA find test manufacturers that can make their tests at a significant scale. The NIH said the goal is to accelerate the availability of more high-quality, accurate over-the-counter tests to the public as quickly as possible. 

“Access to easy-to-use, affordable and reliable COVID tests is key to bringing peace of mind to our families, especially as we approach winter,” HHS Secretary Xavier Becerra said in a news release. 

The NIH program aims to increase over-the-counter testing options to increase overall supply and potentially lower testing costs. 

The FDA also said that it has authorized the 10th over-the-counter COVID-19 test, a rapid antigen test called DiaTrust, made by Celltrion.

Read the full news release here

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.